Neurodegenerative diseases are an increasing challenge for European social welfare and healthcare systems, with a growing number of people affected who often lack effective treatment options.

Public-private partnerships provide an unprecedented opportunity for all concerned parties to work together to improve our current understanding of these conditions, and to create platforms that facilitate the development of new treatments.

The Innovative Medicines Initiative (IMI) is the world’s biggest public-private partnership in life sciences and aims to accelerate the development of better and safer medicines for patients, especially in areas of unmet medical need. This unique platform for collaboration brings together key players who share the joint vision of a healthier future.

In the pursuit of this joint vision, the IMI launched a portfolio of projects that deal with neurodegenerative diseases. These projects aim to better understand the biology of such diseases, discover new targets, define better taxonomies, design innovative tools and provide the foundation to establish new methods of research and development, including initiatives for patient engagement and the use of data from the real world.

For an overview of the projects click here.

The Neuronet initiative has been conceived to link IMI projects with the aim of promoting collaboration between them and raising the visibility of research findings, so that other initiatives and researchers from all over the world can collaborate and contribute towards our common vision of a healthier future for all.